Displaying 1 - 20 of 1722
Vyera Pharmaceuticals, LLC
The Federal Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote banned Shkreli for life from the pharmaceutical industry.
On January 23, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s ruling.
On October 13, 2026, the FTC and seven states asked a federal judge to hold “Pharma Bro” Martin Shkreli in contempt based on their allegations that he flagrantly and repeatedly violated a 2022 court order that banned him from the pharmaceutical industry.
Type of Action
Federal
Last Updated
FTC Matter/File Number
161 0001
Case Status
Pending
Federal Register Notice
Beretta and Ruger; Analysis of Proposed Agreement Containing Consent Order To Aid Public Comment
Date
Federal Register Notice
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
Date
Statement Regarding Fairfield Medical Center’s Sale to Adena Health
Date
On Sept. 1, 2026, Adena Health announced its acquisition of Fairfield Medical Center (FMC), a hospital system in southeastern Ohio. The announcement follows a Federal Trade Commission investigation of...
FTC Approves Final Consent Order in Ascension Health-AmSurg Deal
Date
The Federal Trade Commission finalized a consent order involving Ascension Health Alliance’s (Ascension) proposed $3.9 billion acquisition of AmSurg LLC. The FTC’s final consent order requires...
Statement on FTC Win Blocking Loctite, Liquid Nails Construction Adhesive Merger
Date
The Federal Trade Commission secured an important victory in the fight to lower the cost of housing construction materials for Americans by preventing German multinational Henkel AG & Co. KGaA (Henkel...
Statements on the Grant of Early Termination of the FTC’s Investigation of IonQ’s Proposed Acquisition of SkyWater
Date
The Federal Trade Commission granted early termination of its review of quantum computing developer IonQ Inc.’s proposed acquisition of SkyWater Technologies Inc., a quantum chip fabrication company...
Statement of Commissioner Mark R. Meador, In the Matter of IonQ, Inc. and SkyWater Technology, Inc.
Date
By
Mark R. Meador, Commissioner
Matter Number
2610061
Statement of Chairman Andrew N. Ferguson In the Matter of IonQ, Inc./ SkyWater Technology, Inc.
Date
By
Andrew N. Ferguson, Chairman
Matter Number
2610061
Federal Register Notice
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
Date
FTC Secures $12 Million in Penalties for Pre-Merger Reporting Act Violations
Date
The Federal Trade Commission secured $12 million in penalties to settle charges alleging that Edwards Lifesciences Corp. acquired medical device maker JC Medical from Genesis MedTech Group Limited...
United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Ltd
The Federal Trade Commission secured $12 million in penalties to settle charges alleging that Edwards Lifesciences Corp. acquired medical device maker JC Medical from Genesis MedTech Group Limited without complying with the notification and waiting period requirements of the Hart-Scott-Rodino Act (HSR).
Under the terms of a proposed final judgment Edwards, including former Genesis subsidiary JC Medical, will pay a $10 million penalty. Genesis will pay a $2 million penalty. Edwards will also be subject to additional terms including prior notice requirements. The combined $12 million penalty is the largest ever for failing to make an HSR filing.
Type of Action
Federal
Last Updated
Case Status
Pending
Federal Register Notice
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
Date
FTC and DOJ Issue Fiscal Year 2025 Hart-Scott-Rodino Annual Report
Date
The Federal Trade Commission and the Department of Justice’s (DOJ) Antitrust Division released their 48 th Annual Hart-Scott-Rodino (HSR) Report. This report summarizes the agencies’ merger...
Federal Register Notice
Aurobindo and Lannett; Analysis of Proposed Agreement Containing Consent Orders To Aid Public Comment
Date
FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal
Date
The Federal Trade Commission took action to protect American patients from higher drug costs by requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250...
Aurobindo-Lannett, In the Matter of
The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
251 0096
Docket Number
C-4834
Case Status
Pending
FTC Approves Final Consent Order in Micromarket Kiosks Deal
Date
The Federal Trade Commission finalized a consent order involving 365 Retail Markets LLC’s $848 million acquisition of Cantaloupe Inc., a deal which seeks to combine the two largest providers of...
Displaying 1 - 20 of 1722